

Title (en)

NEW CYSTEINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICALS CONTAINING THEM

Title (de)

CYSTEINDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL

Title (fr)

NOUVEAUX DERIVES DE CYSTEINE, LEURS PROCEDES DE PRODUCTION ET PRODUITS PHARMACEUTIQUES LES CONTENANT

Publication

**EP 1034163 A1 20000913 (EN)**

Application

**EP 98924281 A 19980506**

Priority

- EP 98924281 A 19980506
- EP 9802654 W 19980506
- EP 97107495 A 19970507

Abstract (en)

[origin: WO9850351A1] A compound represented by general formula (I), which binds and inhibits matrix metalloproteinases (MMPs), wherein the cysteine moiety contains an unprotected thiol group, the cysteine moiety is in the L- or D-configuration wherein A denotes -CO-, SO<sub>2</sub>-, -NH-CO-, or -O-CO-, R<sub>1</sub> denotes hydrogen, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C<sub>1</sub>-C<sub>15</sub> alkyl group substituted by halogen, mercapto, hydroxy, alkoxy, amino or nitro, or by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof. R denotes hydroxy, a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms or a C<sub>1</sub>-C<sub>15</sub> alkyl group substituted by carbocyclic non aromatic or aromatic ring systems which are optionally substituted once or several times or aromatic or non aromatic heterocycles, optionally substituted, their pharmacologically acceptable salts, or optically active forms thereof, processes for the preparation, pharmaceutical compositions and their use in medicine.

IPC 1-7

**C07C 323/60**; **C07D 213/40**; **C07D 209/16**; **A61K 31/16**; **A61K 31/27**; **A61K 31/44**; **A61K 31/40**

IPC 8 full level

**A61K 31/16** (2006.01); **A61K 31/27** (2006.01); **A61K 31/40** (2006.01); **A61K 31/405** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4409** (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01); **C07C 323/60** (2006.01); **C07D 209/16** (2006.01); **C07D 213/40** (2006.01); **C07D 213/56** (2006.01)

CPC (source: EP KR)

**A61P 19/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 323/60** (2013.01 - EP KR); **C07D 209/16** (2013.01 - EP); **C07D 213/40** (2013.01 - EP)

Citation (search report)

See references of WO 9850351A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

**WO 9850351 A1 19981112**; AU 7652998 A 19981127; BR 9808758 A 20001003; CA 2289094 A1 19981112; CN 1261878 A 20000802; EP 1034163 A1 20000913; JP 2001525800 A 20011211; KR 20010012321 A 20010215; TR 199903120 T2 20000522; ZA 983792 B 19991108

DOCDB simple family (application)

**EP 9802654 W 19980506**; AU 7652998 A 19980506; BR 9808758 A 19980506; CA 2289094 A 19980506; CN 98806716 A 19980506; EP 98924281 A 19980506; JP 54773498 A 19980506; KR 19997010273 A 19991106; TR 9903120 T 19980506; ZA 983792 A 19980506